Jefferson Life Sciences: Investment Portfolio & Startup News

OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform

OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems in endocrinology and immunology. OMass Therapeutics develops OMS1620 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome and advances an SLC15A4 inhibitor for lupus and related diseases.